Zejula can now be used as a maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk after chemotherapy.
The drug slows or stops tumor growth by inhibiting an enzyme that helps the DNA inside cancerous cells repair itself.
More than 22,000 women will be diagnosed with these three cancers in 2017 and more than 14,000 will die, according to estimates from the National Cancer Institutes.
Tesaro expects Zejula to hit the market in late April, according to a company news release.
More articles on supply chain:
How Centura Health eliminated waste and boosted efficiency in its supply chain
6 notable device recalls in 2016
Insys Therapeutics receives DEA approval for synthetic marijuana drug
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
